NCT06679582Phase 1, phase 2Terminated

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

Study sponsor: Sutro Biopharma, Inc. · STRO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-01-21Actual
Enrollment · participants1Actual
Source updated2026-10-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.